REG - Hemogenyx Pharma Plc - FLT3 Assay Ready for Phase I Trials at MD Anderson

Hemogenyx PharmaceuticalsAnnouncement

09/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240909:nRSI3183Da&default-theme=true

RNS Number : 3183D  Hemogenyx Pharmaceuticals PLC  09 September 2024

9 September 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

FLT3 Assay Ready for Phase I Trials at MD Anderson

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical
group focused on developing treatments for cancers and viral diseases, is
pleased to announce the successful completion of the development of a
clinical-grade assay ("Assay") designed to assess FLT3 protein expression in
acute myeloid leukemia ("AML") cells.

 

Assessing FLT3 protein expression in AML cells is crucial for the accurate
identification and recruitment of patients for the imminent Phase I clinical
trials of the Company's HEMO-CAR-T product candidate. The trials are expected
to commence shortly at MD Anderson Cancer Center ("MD Anderson
(https://www.mdanderson.org/) "), one of the world's most respected centers
devoted exclusively to cancer patient care, research, education and
prevention. The Phase I clinical trials are planned to expand to the
University of Pennsylvania Medical Center thereafter.

 

Dr Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"The completion of our FLT3 assay marks a critical milestone in advancing our
HEMO-CAR-T product candidate into clinical trials. This Assay will ensure we
can accurately identify and recruit the right patients for the trials,
bringing us one step closer to providing a potentially life-saving treatment
for those battling AML. We are excited to begin our Phase I trials imminently
at MD Anderson Cancer Center, a leading institution in cancer care, and look
forward to expanding our efforts to the University of Pennsylvania Medical
Center."

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

 

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

About AML

AML, the most common type of acute leukemia in adults, has poor survival rates
(a five-year survival rate of less than 30% in adults) and is currently
treated using chemotherapy, rather than the potentially more benign and
effective form of therapy being developed by Hemogenyx Pharmaceuticals. The
successful development of the new therapy for AML would have a major impact on
treatment and survival rates for the disease.

About ALL

Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow
that primarily affects children, although it can also occur in adults. Unlike
Acute Myeloid Leukemia (AML), ALL is characterized by the rapid proliferation
of immature lymphocytes, a type of white blood cell. ALL is the most common
childhood cancer, representing approximately 25% of cancer diagnoses in
children. It progresses quickly and requires prompt treatment. While the
overall prognosis for ALL is generally more favorable than AML, certain
subtypes remain challenging to treat. Hemogenyx Pharmaceuticals is developing
innovative treatments specifically targeting a subset of ALL that has proven
particularly difficult to treat, especially in children. The Company's R&D
focuses on addressing the limitations of current therapies and improving
outcomes for patients with these hard-to-treat forms of ALL.

About MD Anderson

 

The University of Texas MD Anderson Cancer Center is one of the world's most
respected centers devoted exclusively to cancer patient care, research,
education and prevention. The mission of the MD Anderson is to eliminate
cancer in Texas, the USA, and the world through outstanding programs that
integrate patient care, research and prevention, and through education for
undergraduate and graduate students, trainees, professionals, employees and
the public.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLFMRTMTBMBFI